Adalimumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
Pralatrexate
Antimetabolite · Antineoplastic
AntimetaboliteAntineoplastic
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 12 →
- AdalimumabSevereDatabaseDDInter
- BaricitinibSevereDatabaseDDInter
- CertolizumabSevereDatabaseDDInter
- CladribineSevereDatabaseDDInter
Mechanism
Pralatrexate is an antimetabolite that functions as a folate antagonist. It has an increased capacity for transport into tumor cells compared to older agents. Pralatrexate primarily exerts its inhibitory effect on thymidylate synthase (TS), an enzyme crucial for DNA synthesis.
Indications
cutaneous T-cell lymphoma (CTCL)
Dosing
- Adult
- of a lethal effect caused by multiple insults to the same organ system by different drugs and allows dose intensity to be maximized. 3. Optimum scheduling: Drugs should be used in their optimal dose and schedule, and drug combinations should be administered at consistent intervals.…
Drug interactions
Baricitinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Certolizumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cladribine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Clozapine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Deferiprone
Severe
Database
Clinical effect not specified
Source: DDInter
Etanercept
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Fingolimod
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Golimumab
Severe
Database
Clinical effect not specified
Source: DDInter
Infliximab
Severe
Database
Clinical effect not specified
Source: DDInter
Leflunomide
Severe
Database
Clinical effect not specified
Source: DDInter
Lomitapide
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Other Antimetabolite drugs
Ask House about Pralatrexate
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung·Verified: 2026-05-13 · House clinical team